Printer Friendly
The Free Library
4,491,676 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Alnylam Added to NASDAQ Biotechnology Index.


CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it will be added to the NASDAQ Biotechnology Index (Nasdaq: NBI NBI - Narrow Band Interference
NBI - Nation Brands Index (statistics)
NBI - National Bridge Inventory
NBI - National Bureau of Investigation
NBI - Net Business Income
NBI - Network Business Intelligence
NBI - Neutral Beam Interface
NBI - Neutron Beam Injector
NBI - Nevada Biodiversity Initiative
NBI - New Business Initiative
NBI - Newcastle Bioinformatics Initiative (Australia)
NBI - NextWave Broadband Inc
NBI - Niels Bohr Institute (Denmark)
), effective with the U.S. market open on Monday, November 14, 2005.

"We are proud to be selected to join the NASDAQ Biotechnology Index," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam Pharmaceuticals. "We believe our inclusion in this index reflects the increased awareness in the investment community of the potential of RNAi for therapeutic applications, and the importance of translating this breakthrough in biology into innovative medicines."

The NASDAQ Biotechnology Index was launched in 1993 and includes biotechnology and pharmaceutical companies listed on the NASDAQ National Market that meet minimum requirements for market value, average daily share volume and seasoning as a public company. The NASDAQ Biotechnology Index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares NASDAQ Biotechnology Index Fund(SM) (AMEX:IBB). For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.

About Alnylam

Alnylam is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi. The company, founded in 2002 by scientific pioneers in the field of RNAi, maintains a leadership position in fundamental patents, technology, and know-how relating to RNAi. Alnylam is applying its expertise in RNAi to address multiple therapeutic opportunities that cannot effectively be addressed with small molecules or antibodies, the two current major classes of drugs. The company's expertise in designing and optimizing RNAi therapeutics has enabled Alnylam to form major alliances with leading companies including Merck, Medtronic, and Novartis. The company's global headquarters are in Cambridge, Massachusetts, with an additional operating unit in Kulmbach Kulmbach, town (1994 pop. 28,260), Bavaria, central Germany, on the White Main River. Known in 1035, Kulmbach became (1340) the residence of the margraves of Kulmbach (later known as the margraves of Bayreuth) of the house of Hohenzollern. In 1791 the town passed to Prussia, in 1807 it was taken by France, and in 1810 it was annexed by Bavaria and made part of Upper Franconia. On a nearby hill is the fortress (now a museum) of Plassenburg (12th cent., Germany. For more information, please visit www.alnylam.com.

Alnylam Forward-Looking Statements

Various statements in this release concerning our future expectations, plans and prospects, such as the company's inclusion in the NASDAQ Biotechnology Index, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales and distribution of our products; the successful development of products, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; obtaining, maintaining and protecting intellectual property utilized by our products; our dependence on collaborators; and our short operating history; as well as those risks more fully discussed in the "Certain Factors That May Affect Future Results" section of our most recent quarterly report on Form 10-Q on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We do not assume any obligation to update any forward-looking statements.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Nov 14, 2005
Words:542
Previous Article:Excelligence Learning Corporation Announces Delay in Filing of Form 10-Q and Request for Further Filing Extension From Nasdaq.
Next Article:Admiral Bay Welcomes Thomas R. Tough To The Board.
Topics:



Related Articles
Alnylam to Webcast Presentation at the Annual BIO Investor Forum on October 19, 2005.
Alnylam to Webcast Presentation at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on November 8, 2005.
Panacos Added to NASDAQ Biotechnology Index.
Alnylam to Webcast its R&D Day on Wednesday, December 14, 2005.
Alnylam Announces Pandemic Flu as Next Development Program; Obtains Initial Federal Funding to Develop RNAi Therapeutics for Pandemic Influenza and...
Novartis and Alnylam Announce New Collaboration to Develop RNAi Therapeutics for Pandemic Flu.
Novartis and Alnylam Announce New Collaboration to Develop RNAi Therapeutics for Pandemic Flu.
Alnylam to Host Conference Call to Discuss Collaboration with Novartis to Develop RNAi Therapeutics for Pandemic Flu.
Alnylam to Webcast Presentation at the Bear Stearns Biotech Boston Confab.
OMRIX Biopharmaceuticals To Join NASDAQ Biotechnology Index(R).

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles